Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01691898
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell, Lymphoma, Follicular
Interventions: Drug: DCDS4501A;   Drug: DCDT2980S;   Drug: rituximab [MabThera/Rituxan]

Indicates status has not been verified in more than two years